This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development.
People who live in rural and remote areas have specific challenges in accessing cancer treatments and preventive services. It is estimated that up to 20% of the U.S.
Twenty five groups joined to ask the HHS Office of Inspector General (OIG) to create a safe harbor from the Anti-Kickback Statute (AKS) allowing sponsors to financially support participants in cancer clinical trials.
Over 130 organizations have endorsed the Clinical Trial Modernization Act (H.R. 3521). The legislation would address known barriers to cancer clinical trial participation, enabling financial and technical support of patients enrolled on trials while protecting them from unexpected tax burdens from that support.
